Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Perfusion Therapy for Extremity Melanoma

Perfusion Therapy for Extremity Melanoma Abstract • Because of their initial appearance on extremities, malignant melanomas lend themselves to isolated chemotherapeutic perfusions. Perfusion is attractive because one can deliver effective cytotoxic drugs without systemic toxicity. We are reviewing 20 patients treated between 1960 and 1973 with isolated perfusion. Melphalan (L-phenylalanine mustard) was the drug of choice. Eleven of the 20 patients had previous surgical treatment. Three of the 11 patients are still alive from 27 to 72 months postperfusion. Eight died after an average survival time of 33 months. Of the seven patients who underwent perfusion as primary therapy, four patients are alive from 25 to 76 months postperfusion, and three died after an average survival time of 34 months. There is direct correlation between stages and levels of melanoma, and perfusion and prolonged survival time. (Arch Surg 111:961-963, 1976) References 1. Creech O Jr, Krementz ET, Ryan RF, et al: Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit . Ann Surg 148:616-632, 1958.Crossref 2. Stehlin JS Jr, Clark RL: Melanoma of the extremities: Experiences with conventional treatment and perfusion in 339 cases . Am J Surg 110:365-383, 1965.Crossref 3. Stehlin JS Jr: Hyperthermic perfusion with chemotherapy for cancers of the extremities . Surg Gynecol Obstet 129:305-308, 1969. 4. Krementz ET, Ryan RF: Chemotherapy of melanoma of the extremities by perfusion: Fourteen years' clinical experience . Ann Surg 175:900-917, 1972.Crossref 5. Shingleton WW: Perfusion chemotherapy for recurrent melanoma of extremity—a progress report . Bull Soc Int Chir 6:354-355, 1970. 6. Alrich EM, Manwaring JL, Horsley JS: Isolation perfusion—an adjunct to surgical excision in the primary treatment of melanoma of the extremities . Am J Surg 121:583-585, 1971.Crossref 7. McBride CM, Clark RL: Experience with L-phenalalinine mustard dihydrochloride in isolation perfusion of extremities for malignant melanoma . Cancer 28:1293-1296, 1971.Crossref 8. Rochlin DB, Smart CR: Treatment of malignant melanoma by regional perfusion . Cancer 18:1544-1550, 1965.Crossref 9. Golomb FM: Perfusion of melanoma . Oncology 26:197-205, 1972.Crossref 10. Clark WH, From L, Bernardino EA, et al: The histogenesis and biologic behavior of primary human malignant melanoma of the skin . Cancer Res 29:705-727, 1969. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Surgery American Medical Association

Perfusion Therapy for Extremity Melanoma

Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/perfusion-therapy-for-extremity-melanoma-D0P3ujdDJN

References (12)

Publisher
American Medical Association
Copyright
Copyright © 1976 American Medical Association. All Rights Reserved.
ISSN
0004-0010
eISSN
1538-3644
DOI
10.1001/archsurg.1976.01360270033005
Publisher site
See Article on Publisher Site

Abstract

Abstract • Because of their initial appearance on extremities, malignant melanomas lend themselves to isolated chemotherapeutic perfusions. Perfusion is attractive because one can deliver effective cytotoxic drugs without systemic toxicity. We are reviewing 20 patients treated between 1960 and 1973 with isolated perfusion. Melphalan (L-phenylalanine mustard) was the drug of choice. Eleven of the 20 patients had previous surgical treatment. Three of the 11 patients are still alive from 27 to 72 months postperfusion. Eight died after an average survival time of 33 months. Of the seven patients who underwent perfusion as primary therapy, four patients are alive from 25 to 76 months postperfusion, and three died after an average survival time of 34 months. There is direct correlation between stages and levels of melanoma, and perfusion and prolonged survival time. (Arch Surg 111:961-963, 1976) References 1. Creech O Jr, Krementz ET, Ryan RF, et al: Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit . Ann Surg 148:616-632, 1958.Crossref 2. Stehlin JS Jr, Clark RL: Melanoma of the extremities: Experiences with conventional treatment and perfusion in 339 cases . Am J Surg 110:365-383, 1965.Crossref 3. Stehlin JS Jr: Hyperthermic perfusion with chemotherapy for cancers of the extremities . Surg Gynecol Obstet 129:305-308, 1969. 4. Krementz ET, Ryan RF: Chemotherapy of melanoma of the extremities by perfusion: Fourteen years' clinical experience . Ann Surg 175:900-917, 1972.Crossref 5. Shingleton WW: Perfusion chemotherapy for recurrent melanoma of extremity—a progress report . Bull Soc Int Chir 6:354-355, 1970. 6. Alrich EM, Manwaring JL, Horsley JS: Isolation perfusion—an adjunct to surgical excision in the primary treatment of melanoma of the extremities . Am J Surg 121:583-585, 1971.Crossref 7. McBride CM, Clark RL: Experience with L-phenalalinine mustard dihydrochloride in isolation perfusion of extremities for malignant melanoma . Cancer 28:1293-1296, 1971.Crossref 8. Rochlin DB, Smart CR: Treatment of malignant melanoma by regional perfusion . Cancer 18:1544-1550, 1965.Crossref 9. Golomb FM: Perfusion of melanoma . Oncology 26:197-205, 1972.Crossref 10. Clark WH, From L, Bernardino EA, et al: The histogenesis and biologic behavior of primary human malignant melanoma of the skin . Cancer Res 29:705-727, 1969.

Journal

Archives of Surgery – American Medical Association

Published: Sep 1, 1976

There are no references for this article.